Biomarker ID | 1246 |
PMID | 24240687 |
Year | 2013 |
Biomarker | N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 ) |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Increased in Biochemical Recurrence |
Odds Ratio/Hazard Ratio/Relative Risk | Univariate Analysis: HR: [1.9 (95% CI: 1.1 - 3.4)] ; Multivariate Analysis: HR: [1.7 (95% CI: 0.9 - 3.1)] |
Effect on Pathways | Pathways include: SGK494 human kinase ARCHS4 coexpression, SCYL3 human kinase ARCHS4 coexpression, AURKC human kinase ARCHS4 coexpression, BMPR1B human kinase ARCHS4 coexpression, RPS6KA5 human kinase ARCHS4 coexpression |
Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
Type of Biomarker | Prognostic |
Cohort | 252 patients with Prostate cancer were chosen out of which 101 experienced recurrence |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | 65.3% |
Level Of Significance | Univariate: p = 0.0038; Multivariate: p =0.036 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NAALADL2 |